Chapter 18 Current therapy of the Lambert-Eaton myasthenic syndrome

Anderson, 1953, Bronchial neoplasm with myasthenia: prolonged apnoea after administration of succinylcholine, Lancet, ii, 1291, 10.1016/S0140-6736(53)91358-0 Cherington, 1976, Guanidine and germine in Eaton-Lambert syndrome, Neurology (Minneap.), 26, 944, 10.1212/WNL.26.10.944 Cull-Candy, 1976, Effects of botulinum toxin on neuromuscular transmission in the rat, J. Physiol. (Lond.), 260, 177, 10.1113/jphysiol.1976.sp011510 Dau, 1981, Plasmapheresis and immunosuppressive drug therapy in Eaton-Lambert syndrome, Ann. Neurol., 11, 570, 10.1002/ana.410110604 Fukunaga, 1982, Paucity and disorganization of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome, Muscle Nerve, 5, 686, 10.1002/mus.880050905 Fukuoka, 1987, Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones, Ann. Neurol., 22, 193, 10.1002/ana.410220203 Fukuoka, 1987, Lambert-Eaton myasthenic syndrome. II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate, Ann. Neurol., 22, 200, 10.1002/ana.410220204 Henriksson, 1977, Clinical, neurophysiological and morphological findings in Eaton-Lambert syndrome, Acta Neurol. Scand., 56, 117, 10.1111/j.1600-0404.1977.tb01417.x Henson, 1953, Discussion of unusual manifestation of bronchial carcinoma, Proc. R. Soc. Med., 46, 859 Kamenskaya, 1975, Guanidine and neuromuscular transmission, Arch. Neurol. (Chicago), 32, 505, 10.1001/archneur.1975.00490500025001 Lambert, 1966, Defects of neuromuscular transmission in syndromes other than myasthenia gravis, Ann. N. Y. Acad. Sci., 135, 367, 10.1111/j.1749-6632.1966.tb45484.x Lambert, 1971, Quantal components of end-plate potentials in the myasthenic syndrome, Ann. N. Y. Acad. Sci., 183, 183, 10.1111/j.1749-6632.1971.tb30750.x Lambert, 1965, Myasthenic state and lung cancer, 67 Lambert, 1956, Defect of neuromuscular conduction associated with malignant neoplasms, Am. J. Physiol., 187, 612 Lang, 1983, Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse, J. Physiol. (Lond.), 344, 335, 10.1113/jphysiol.1983.sp014943 Lang, 1981, Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome, Lancet, ii, 224, 10.1016/S0140-6736(81)90474-8 Lemeignan, 1984, Evaluation of 4-aminopyridine and 3, 4-diamino-pyridine penetrability into cerebrospinal fluid in anesthetized rats, Brain Res., 304, 166, 10.1016/0006-8993(84)90875-8 Llinás, 1982, 3-and 4-aminopyridine in synaptic transmission at the giant synapse, Vol. 35, 69 Lundh, 1978, Effects of 4-aminopyridine on neuromuscular transmission, Brain Res., 153, 307, 10.1016/0006-8993(78)90409-2 Lundh, 1982, Therapeutic applications of aminopyridines in diseases of neuromuscular transmission, Vol. 35, 287 Lundh, 1977, The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals, Eur. J. Pharmacol., 42, 411, 10.1016/0014-2999(77)90176-5 Lundh, 1981, An extrapyramidal choreiform syndrome caused by amphetamine addiction, J. Neurol. Neurosurg. Psychiatry, 44, 728, 10.1136/jnnp.44.8.728 Lundh, 1977, Antagonism of the paralysis produced by botulinum toxin in the rat, J. Neurol. Sci., 32, 29, 10.1016/0022-510X(77)90037-5 Lundh, 1977, 4-Aminopyridine: a new drug tested in the treatment of Eaton-Lambert syndrome., J. Neurol. Neurosurg. Psychiatry, 40, 1109, 10.1136/jnnp.40.11.1109 Lundh, 1983, Novel drug of choice in Eaton-Lambert syndrome, J. Neurol. Neurosurg. Psychiatry, 46, 684, 10.1136/jnnp.46.7.684 Lundh, 1984, Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine, Neurology (Cleveland), 34, 1324, 10.1212/WNL.34.10.1324 Molenaar, 1982, Eaton-Lambert syndrome: acetylcholine and choline acetyltransferase in skeletal muscle, Neurology (New York), 32, 1061, 10.1212/WNL.32.9.1061 Molgó, 1988, The mode of action of guanidine on mouse motor nerve terminals, Neurosci. Lett., 89, 161, 10.1016/0304-3940(88)90374-6 Molgó, 1980, Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes, Eur. J. Pharmacol., 61, 25, 10.1016/0014-2999(80)90378-7 Murray, 1981, Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission, Neurology (New York), 31, 265, 10.1212/WNL.31.3.265 Newsom-Davis, 1984, Plasma exchange and immunosuppressive drug treatment in Lambert-Eaton myasthenic syndrome, Neurology (Cleveland), 34, 480, 10.1212/WNL.34.4.480 Nilsson, 1978, The stretch reflex in the Eaton Lambert syndrome, myasthenia gravis and myotonic dystrophy, Acta Neurol. Scand., 57, 350 Oh, 1973, Guanidine hydrochloride in Eaton-Lambert syndrome, Neurology. (Minneap.), 23, 1084, 10.1212/WNL.23.10.1084 O’Neill, 1988, The Lambert-Eaton myasthenic syndrome. A review of 50 cases, Brain, 111, 577, 10.1093/brain/111.3.577 Pumplin, 1981, Are the presynaptic membrane particles the calcium channels?, Proc. Natl. Acad. Sci. USA, 78, 7210, 10.1073/pnas.78.11.7210 Sanders, 1980, Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine, J. Neurol. Neurosurg. Psychiatry, 43, 978, 10.1136/jnnp.43.11.978 Simpson, 1986, Molecular pharmacology of botulinum toxin and tetanus toxin, Annu. Rev. Pharmacol. Toxicol., 26, 427, 10.1146/annurev.pa.26.040186.002235 Streib, 1981, Eaton-Lambert myasthenic syndrome: Long-term treatment of three patients with prednisone, Ann. Neurol., 10, 448, 10.1002/ana.410100507 Wray, 1987, Interference with calcium channels by Lambert Eaton myasthenic syndrome antibody, Ann. N. Y. Acad. Sci., 505, 368, 10.1111/j.1749-6632.1987.tb51305.x Yeh, 1976, Interactions of aminopyridines with potassium channels of squid axon membranes, Biophys. J., 16, 77, 10.1016/S0006-3495(76)85663-9